C-Met/Pd-L1 Car-T Cell
Primary Hepatocellular Carcinoma
The Second Hospital of Nanjing Medical UniversityCell therapyEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
521 Active assets in the Primary Hepatocellular Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Adefovir Bukwang Pharmaceutical | Phase 4 | BBB |
Huaier Granule Tongji Hospital | Phase 4 | BBB |
Sorafenib Bayer | Phase 4 | BBB |
Carboplatin AstraZeneca | Phase 4 | BB |
Theprubicin RWTH Aachen University | Phase 4 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →